Literature DB >> 6874524

Bovine anaplasmosis: elimination of the carrier state with injectable long-acting oxytetracycline.

B L Swift, G M Thomas.   

Abstract

Long-acting oxytetracycline was administered intramuscularly (20 mg/kg) at 3-day intervals to each of 16 naturally infected Anaplasma marginale carrier beef cows; 8 of the 16 cows were given 3 injections and the other 8 cows were given 4 injections. Four cows seropositive for A marginale served as untreated controls. Rapid card agglutination and complement fixation tests were performed 5 times during the 130-day posttreatment period. All treated cows became negative to both serologic procedures, whereas control cows remained seropositive. Three splenectomized calves that received pooled blood from the treated cows, 120 days following treatment, remained free of anaplasmosis for 60 days following inoculation. One splenectomized calf that received blood from the control cows developed anaplasmosis. It was concluded that long-acting oxytetracycline can be used to eliminate the naturally acquired carrier state of anaplasmosis in cattle.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6874524

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  12 in total

1.  Efficacy of a doxycycline treatment regimen initiated during three different phases of experimental ehrlichiosis.

Authors:  Jennifer C McClure; Michelle L Crothers; John J Schaefer; Patrick D Stanley; Glen R Needham; S A Ewing; Roger W Stich
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Comparison of surface proteins of Anaplasma marginale grown in tick cell culture, tick salivary glands, and cattle.

Authors:  A F Barbet; R Blentlinger; J Yi; A M Lundgren; E F Blouin; K M Kocan
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Evaluation of Anaplasma marginale major surface protein 3 (MSP3) as a diagnostic test antigen.

Authors:  A R Alleman; A F Barbet
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

4.  Anaplasma marginale major surface protein 3 is encoded by a polymorphic, multigene family.

Authors:  A R Alleman; G H Palmer; T C McGuire; T F McElwain; L E Perryman; A F Barbet
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

5.  Expression of members of the 28-kilodalton major outer membrane protein family of Ehrlichia chaffeensis during persistent infection.

Authors:  Jian-zhi Zhang; Hong Guo; Gary M Winslow; Xue-jie Yu
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

6.  Presence of common antigens, including major surface protein epitopes, between the cattle (intraerythrocytic) and tick stages of Anaplasma marginale.

Authors:  G H Palmer; K M Kocan; S J Barron; J A Hair; A F Barbet; W C Davis; T C McGuire
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

7.  Identification of Anaplasma marginale long-term carrier cattle by detection of serum antibody to isolated MSP-3.

Authors:  T C McGuire; W C Davis; A L Brassfield; T F McElwain; G H Palmer
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

8.  The Anaplasma marginale msp5 gene encodes a 19-kilodalton protein conserved in all recognized Anaplasma species.

Authors:  E S Visser; T C McGuire; G H Palmer; W C Davis; V Shkap; E Pipano; D P Knowles
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

9.  Detection of an Anaplasma marginale common surface protein present in all stages of infection.

Authors:  G H Palmer; A F Barbet; K L Kuttler; T C McGuire
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

10.  Development of a subcutaneous ear implant to deliver an anaplasmosis vaccine to dairy steers.

Authors:  Andrew K Curtis; Kathryn E Reif; Michael D Kleinhenz; Miriam S Martin; Brandt Skinner; Sean M Kelly; Douglas E Jones; Robert G Schaut; Emily J Reppert; Shawnee R Montgomery; Balaji Narasimhan; Tippawan Anantatat; Majid Jaberi-Douraki; Johann F Coetzee
Journal:  J Anim Sci       Date:  2020-06-01       Impact factor: 3.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.